Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01925638 · ClinicalTrials.gov registry record · Phase 1
Effect of Ketoconazole on the Pharmacokinetics of Refametinib
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01925638 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 18 participants.
The verdict
NCT01925638, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to see if there is a difference between the way your body absorbs and distributes BAY86-9766 when given alone or in combination with ketoconazole, a drug which may affect how much BAY86-9766 is absorbed, distributed or eliminated from the body
Interventions
- DRUG Ketoconazole
- DRUG BAY86-9766
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01925638
The ClinicalTrials.gov registry entry for NCT01925638 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketoconazole is the first listed.
NCT01925638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01925638 about?
NCT01925638 is a clinical study titled "Effect of Ketoconazole on the Pharmacokinetics of Refametinib". The purpose of this study is to see if there is a difference between the way your body absorbs and distributes BAY86-9766 when given alone or in combination with ketoconazole, a drug which may affect how much BAY86-9766 is absorbed, distributed or eliminated from the body
What is the current status of trial NCT01925638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01925638?
The interventions under investigation include: Ketoconazole (DRUG), BAY86-9766 (DRUG).
Who is sponsoring clinical trial NCT01925638?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.